通过抑制细胞糖酵解,糠酸酮在甲状腺癌中的抗肿瘤活性。

Antitumor activity of Koningic acid in thyroid cancer by inhibiting cellular glycolysis.

机构信息

Department of Endocrinology, The First Hospital of Yulin, 719000, Yulin, PR China.

Department of Endocrinology, The First Affiliated Hospital of Xi'an Jiaotong University, 710061, Xi'an, PR China.

出版信息

Endocrine. 2022 Jan;75(1):169-177. doi: 10.1007/s12020-021-02822-x. Epub 2021 Jul 15.

Abstract

PURPOSE

Koningic acid (KA), a sesquiterpene lactone, has been identified as an antimicrobial agent. Recent studies have revealed KA's antitumor activities in colorectal cancer, leukemia, and lung cancer. However, its antitumor effect in thyroid cancer remains largely unknown.

METHODS

The effects of KA on proliferation, colony formation, apoptosis in thyroid cancer cells were assessed by MTT assay and flow cytometry. After KA treatment, the glycolysis ability of thyroid cancer cells was detected by ECAR, and the glycolytic products and relative ATP levels were measured by ELISA. The underlying mechanisms of antineoplastic activity of KA in thyroid cancer were detected by Western blot. Finally, the antineoplastic activity in vivo was observed in Xenograft mouse models.

RESULTS

KA inhibited the proliferation, colony formation, and increased cell apoptosis in thyroid cancer cell lines in a dose and time-dependent manner. We verified that the glycolysis ability, ATP production, and lactic acid level in thyroid cancer cells had experienced an extensive decrease after KA treatment. In addition, lactic acid, the metabolite of glycolysis, could weaken the effect of KA on its colony formation ability in C643 thyroid cancer cell line. Our data also showed that KA kills thyroid cancer cells by inhibiting the MAPK/ERK pathway and decreasing Bcl-2 level. By contrast with the control group, the growth of xenograft tumor was dramatically inhibited by KA without obvious drug side effects.

CONCLUSION

Our data demonstrate that KA kills thyroid cancer cell lines by inhibiting their glycolysis ability, the MAPK/ERK pathway and the Bcl-2 level and suggest that KA has potential clinical value in thyroid cancer therapy.

摘要

目的

糠醛酸(KA)是一种倍半萜内酯,已被鉴定为一种抗菌剂。最近的研究表明,KA 在结直肠癌、白血病和肺癌中具有抗肿瘤活性。然而,其在甲状腺癌中的抗肿瘤作用在很大程度上尚不清楚。

方法

通过 MTT 检测和流式细胞术评估 KA 对甲状腺癌细胞增殖、集落形成、凋亡的影响。KA 处理后,通过 ECAR 检测甲状腺癌细胞的糖酵解能力,并通过 ELISA 测量糖酵解产物和相对 ATP 水平。通过 Western blot 检测 KA 在甲状腺癌细胞中的抗肿瘤活性的潜在机制。最后,在 Xenograft 小鼠模型中观察体内抗肿瘤活性。

结果

KA 呈剂量和时间依赖性地抑制甲状腺癌细胞系的增殖、集落形成,并增加细胞凋亡。我们验证了 KA 处理后甲状腺癌细胞的糖酵解能力、ATP 产生和乳酸水平经历了广泛下降。此外,糖酵解的代谢产物乳酸可削弱 KA 对其集落形成能力的影响在 C643 甲状腺癌细胞系中。我们的数据还表明,KA 通过抑制 MAPK/ERK 通路和降低 Bcl-2 水平杀死甲状腺癌细胞。与对照组相比,KA 显著抑制异种移植肿瘤的生长,而无明显的药物副作用。

结论

我们的数据表明,KA 通过抑制其糖酵解能力、MAPK/ERK 通路和 Bcl-2 水平杀死甲状腺癌细胞系,并表明 KA 在甲状腺癌治疗中具有潜在的临床价值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c20/8763937/c46b7d49be6e/12020_2021_2822_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索